US Oncologists to Prescribe Enzalutamide for Metastatic Castration-resistant Prostate cancer (mCRPC)
Metastatic Castration-Resistant Prostate Cancer is an advanced form of prostate cancer that have spread to organs beyond the prostate gland.
This form cancer has resisted hormone therapy, which is usually the first line of treatment for advanced prostate cancer. It is quite dangerous for those affected and can shorten their chances of survival.
That said, there are still treatments options that can help relieve symptoms of this cancer and extend the lives of those affected. Enzalutamide is one of such treatments and has shown to be very effective to increase life expectancy for the patient.
For this reason, US Oncologists have indicated through a recent research that this medication would be prescribed in about 30% of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This would often be administered best as second and third line treatment of the disease. Here are facts about the research conducted on US Oncologists:
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to positive overall survival data from the Phase III AFFIRM trial and interviewed experts’ enthusiasm for this agent, surveyed U.S. oncologists indicate that they would prescribe Medivation/Astellas Pharma’s enzalutamide (formerly MDV-3100) to 30 percent of their second- and third-line metastatic castrate-resistant prostate cancer (mCRPC) patients.
Decision Resources’ analysis of the prostate cancer drug market also finds that interviewed thought leaders believe that Johnson & Johnson/Janssen Biotech/Janssen-Cilag’s Zytiga will experience a shift in use from the second- and third-line mCRPC setting (its current approved indication) to the first-line, chemotherapy-naive mCRPC setting, assuming that Zytiga successfully obtains a supplemental new drug application (sNDA) for this patient population.
Surveyed U.S. oncologists and managed care organization (MCO) pharmacy directors agree that overall survival is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in second- and third-line mCRPC. Clinical data and the opinions of interviewed thought leaders indicate that enzalutamide, Takeda/Millennium’s orteronel and Algeta/Bayer HealthCare’s Alpharadin have advantages on this attribute over docetaxel (Sanofi’s Taxotere, generics), which was the sales leading agent for the indication in 2010.
According to insights from surveyed U.S. oncologists and MCO pharmacy directors, improving symptom control and quality of life is one of the greatest unmet needs in second- and third-line mCRPC. Clinical data and interviewed thought leaders indicate that enzalutamide, Exelixis’s cabozantinib and Alpharadin have demonstrated the potential to partially fulfill this unmet need.
The prostate cancer drug market will more than double over the next decade, increasing from $3.6 billion in 2010 to more than $9 billion in 2020 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This market growth will be driven by the launch and uptake of high-priced promising therapies which were unavailable in 2010 and will collectively earn almost $5.5 billion in 2020. In total, the mCRPC drug market (comprising the first-, second-, and third-line settings) will capture $6 billion by 2020, corresponding to two-thirds of the total prostate cancer market.
“Intense clinical development in the mCRPC setting has yielded significant advances and as additional therapies are approved for mCRPC, it will become an increasingly crowded and competitive space,” said Decision Resources Analyst Khurram Nawaz. “Therapies will need to differentiate themselves from one another if they are to maximize clinical and commercial success.”
Decision Resources’ Robust Market Forecast and Opportunities Analysis
Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2012 advisory service and the DecisionBase 2012 report series. Click here to read the full report.
The research by Decision Resources is quite revealing as it shows the wide range of support for Medivation/Astellas Pharma’s enzalutamide (formerly MDV-3100).
The support for the usage of this medication is solely based on the fact the quality of life for the prostate cancer victim would be improved even as life expectancy for the victims will increase.
It is important to really maximize the use of this drug in the clinics so as to achieve maximum success. More information about this new research should be accessed from the website of Decision Resources.
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Cabozantinib Shows More Efficacy in Treating Metastatic Castration-Resistant Prostate Cancer (CRPC)
- Management of Castration-Resistant Prostate Cancer
- Enzalutamide (MDV3100) – a New Drug from Medivation, can Increase Lifespan for Men with Terminal Prostate Cancer
- Rising Psa In Metastatic Prostate Cancer
- Chemotherapy Prostrate Cancer for Hormone Refractory Metastatic
- Symptoms Metastatic Prostate Cancer To Lung
- Symptoms Metastatic Prostate Cancer To The Lung